Conversation with The Cancer Letter FDA Eager to Approve PD-1 and PD-L1 Drugs in Novel Combinations, New Settings November 11, 2016Vol.42 No.42By Paul Goldberg
Conversation with The Cancer Letter Davidson Moves to Seattle Cancer Consortium October 14, 2016Vol.42 No.38By Paul Goldberg
Conversation with The Cancer LetterFree Perspectives on Clinical Development of PD-1 Drugs October 07, 2016Vol.42 No.37
Conversation with The Cancer Letter NCI’s Care Delivery Research Program Seeks to Involve Scientists from Other Fields September 30, 2016Vol.42 No.36By Paul Goldberg
Conversation with The Cancer Letter OHSU Seeks to Raise another $1 Billion; Keith Todd Describes the Strategy September 23, 2016Vol.42 No.35By Paul Goldberg
Conversation with The Cancer LetterFree Lowy: Implementation Will Depend on NCI Funding in Fiscal Year 2017 and 2018 September 09, 2016Vol.42 No.33By Matthew Bin Han Ong
Conversation with The Cancer Letter Staudt: Foundation Medicine’s “Philanthropy of Data” More Than Doubles GDC Portfolio July 29, 2016Vol.42 No.30By Matthew Bin Han Ong
Conversation with The Cancer Letter Pellini: Data Sharing Central to Mission At Foundation Medicine July 29, 2016Vol.42 No.30By Matthew Bin Han Ong
Conversation with The Cancer Letter Weber: We Cannot Completely Ban Guns From MD Anderson’s Campus July 22, 2016Vol.42 No.29
Conversation with The Cancer Letter Kibbe: Anyone Can Build Search Interface With Open-Source NCI Clinical Trials API July 15, 2016Vol.42 No.28By Matthew Bin Han Ong
